REG - Eden Research plc - Novellus+ Regulatory Authorisation in Chile

Eden ResearchAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260109:nRSI2482Oa&default-theme=true

RNS Number : 2482O  Eden Research plc  09 January 2026

As the information in this release pertains to EDEN RESEARCH PLC, this
announcement is deemed to constitute inside information as stipulated under
the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014
(the "UK MAR"), which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance with the
Company's obligations under Article 17 of the UK MAR. Upon the publication of
this announcement, this inside information is now considered to be in the
public domain.

 

9 January 2026

 

 

Eden Research Plc

("Eden" or "Company")

 

Novellus+ Regulatory Authorisation in Chile

 

Eden receives its first authorisation in South America, in one of the world's
largest wine-exporting markets

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technologies, is pleased to announce that it has received
regulatory authorisation in Chile for the fungicide Novellus+(™). The
approval, granted by the Chilean Ministry of Agriculture, applies to its use
in wine and table grapes to control grey mould (Botrytis cinerea) and powdery
mildew (Uncinula necator). Novellus+ provides excellent protection for grapes
with no residues and can be applied up to one day before harvest. Sipcam Chile
SpA, the local affiliate of Sipcam-Oxon, will be the exclusive distributor.

 

Chile is recognised as one of South America's leading agricultural markets,
driven by strong export demand and a favourable climate for year-round
production. Chile is the third largest wine producer in the Southern
Hemisphere, with a five-year average production of 11.3 million hectolitres
(mhL) per year. Globally, Chile was the fourth-largest wine exporter in 2024,
with approximately 70% of the total production exported. Furthermore, with
nearly 50,000 hectares of table grapes grown, Chile is the second largest
producer and exporter of grapes in the Southern Hemisphere.

 

Overall, the Chilean crop protection market is the fourth-largest market in
LATAM, estimated to be $735 million in 2022 and projected to grow to over $834
million by 2027. Conventional chemical pesticides are rapidly being replaced
by organic and biological solutions as a consequence of the pressure from
consumers and retailers, and this migration to more sustainable solutions has
been set as a priority by the government of Chile
(https://www.prochile.gob.cl/en/export-sectors/agriculture-food-supplies) ,
which is boosting international promotion of its organic food production.

 

Sean Smith, CEO of Eden Research, commented:

 

"The approval of Novellus+(™) in Chile is a milestone for Eden in our effort
to deliver sustainable solutions to growers and to the food chain globally.
The Chilean market is particularly attractive as well-recognised exporters of
grapes and wine with a strong commitment to delivering the highest standards
in their products. Working alongside Sipcam-Oxon, we are excited to expand our
business in one of the fastest-growing markets for biological crop protection.
Moving forward, we intend to expand the Novellus+(™) label to include other
high-value crops. Given the clear intention of the local industry and
regulators to move towards more sustainable agriculture, we are confident that
our first step into South America will deliver excellent results for our
partner, growers, and Eden's stakeholders."

 

-- ENDS --

 

For further information, contact:

 

 Eden Research plc                                                       www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                              01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and joint broker)
 Giles Balleny / Elysia Bough (Corporate Finance)                        020 7220 0500

 Harriet Ward (Corporate Broking)

Dale Bellis (Sales)

 Oberon Capital (Joint Broker)                                           020 3179 5300
 Nick Lovering

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                      eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle
crop destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

Follow Eden on LinkedIn (https://www.linkedin.com/company/eden-research-plc/)
, Twitter (https://twitter.com/edenresearch)  and YouTube
(https://www.youtube.com/@edenresearch580) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REABPMBTMTMMTTF



            Copyright 2019 Regulatory News Service, all rights reserved